Natalia A. Kuzmina
YOU?
Author Swipe
View article: A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein
A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein Open
View article: A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein
A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein Open
View article: Plant‐produced <scp>SARS</scp>‐<scp>CoV</scp>‐2 antibody engineered towards enhanced potency and in vivo efficacy
Plant‐produced <span>SARS</span>‐<span>CoV</span>‐2 antibody engineered towards enhanced potency and in vivo efficacy Open
Summary Prevention of severe COVID‐19 disease by SARS‐CoV‐2 in high‐risk patients, such as immuno‐compromised individuals, can be achieved by administration of antibody prophylaxis, but producing antibodies can be costly. Plant expression …
View article: Author Correction: Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system
Author Correction: Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system Open
complement" but should have been "Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system".
View article: Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system
Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system Open
Antibodies to Ebola virus glycoprotein (EBOV GP) represent an important correlate of the vaccine efficiency and infection survival. Both neutralization and some of the Fc-mediated effects are known to contribute the protection conferred by…
View article: RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques
RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques Open
Antibodies provide critical protective immunity against COVID-19, and the Fc-mediated effector functions and mucosal antibodies also contribute to the protection. To expand the characterization of humoral immunity stimulated by subunit pro…
View article: Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin
Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin Open
Ebola virus (EBOV) and Bundibugyo virus (BDBV) belong to the family Filoviridae and cause a severe disease in humans. We previously isolated a large panel of monoclonal antibodies from B cells of human survivors from the 2007 Uganda BDBV o…
View article: Ebolavirus Species-Specific Interferon Antagonism Mediated by VP24
Ebolavirus Species-Specific Interferon Antagonism Mediated by VP24 Open
Members of the Ebolavirus genus demonstrate a marked differences in pathogenicity in humans with Ebola (EBOV) being the most pathogenic, Bundibugyo (BDBV) less pathogenic, and Reston (RESTV) is not known to cause a disease in humans. The V…
View article: Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system
Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system Open
View article: Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies
Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies Open
Hantaviruses are high-priority emerging pathogens carried by rodents and transmitted to humans by aerosolized excreta or, in rare cases, person-to-person contact. While infections in humans are relatively rare, mortality rates range from 1…
View article: Author response: Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies
Author response: Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies Open
Article Figures and data Abstract Editor's evaluation Introduction Results Discussion Materials and methods Data availability References Decision letter Author response Article and author information Metrics Abstract Hantaviruses are high-…
View article: Coronavirus Immunotherapeutic Consortium Database
Coronavirus Immunotherapeutic Consortium Database Open
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has seen multiple anti-SARS-CoV-2 antibodies being generated globally. It is difficult, however, to assemble a usef…
View article: Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection
Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection Open
Adaptive immunity mediated by antibodies is important for controlling SARS-CoV-2 infection. While vaccines against COVID-19 are currently widely distributed, a high proportion of the global population is still unvaccinated.
View article: A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2 Open
The development of safe and effective vaccines to respond to COVID-19 pandemic/endemic remains a priority. We developed a novel subunit protein-peptide COVID-19 vaccine candidate (UB-612) composed of: (i) receptor binding domain of SARS-Co…
View article: IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern Open
Monoclonal antibodies are a promising approach to treat COVID-19, however the emergence of SARS-CoV-2 variants has challenged the efficacy and future of these therapies. Antibody cocktails are being employed to mitigate these challenges, b…
View article: IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern Open
Monoclonal antibodies are a promising approach to treat COVID-19, however the emergence of SARS-CoV-2 variants has challenged the efficacy and future of these therapies. Antibody cocktails are being employed to mitigate these challenges, b…
View article: sPLA2 Wobbles on the Lipid Bilayer between Three Positions, Each Involved in the Hydrolysis Process
sPLA2 Wobbles on the Lipid Bilayer between Three Positions, Each Involved in the Hydrolysis Process Open
Secreted phospholipases A2 (sPLA2s) are peripheral membrane enzymes that hydrolyze phospholipids in the sn-2 position. The action of sPLA2 is associated with the work of two active sites. One, the interface binding site (IBS), is needed to…
View article: Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies
Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies Open
Hantaviruses are high-priority emerging pathogens carried by rodents and transmitted to humans by aerosolized excreta or, in rare cases, person-to-person contact. While sporadic in North and South America, many infections occur in Europe a…
View article: Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region
Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region Open
The three human pathogenic ebolaviruses: Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) virus, cause severe disease with high fatality rates. Epitopes of ebolavirus glycoprotein (GP) recognized by antibodies with binding breadth for all…
View article: A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2 Open
View article: Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19
Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19 Open
Young adults infected with SARS-CoV-2 are frequently asymptomatic or develop only mild disease. Because capturing representative mild and asymptomatic cases require active surveillance, they are less characterized than moderate or severe c…
View article: Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2 Open
View article: COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models Open
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effec…
View article: Pan-ebolavirus protective therapy by two multifunctional human antibodies
Pan-ebolavirus protective therapy by two multifunctional human antibodies Open
View article: A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19 Open
View article: Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects
Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects Open
Fc effector functions and antibody specificity, rather than IgG or neutralizing titers, may serve as protective correlates for Ebola vaccines.
View article: Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection
Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection Open
(Cell Reports 35, 109086-1–13.e1–e9; May 4, 2021) In the originally published version of this article, the incorrect DOI was listed. The original/source data for all figures can be found at https://doi.org/10.17632/36yhsg4b36.1. The paper …
View article: Protective pan-ebolavirus combination therapy by two multifunctional human antibodies
Protective pan-ebolavirus combination therapy by two multifunctional human antibodies Open
Ebolaviruses cause a severe and often fatal illness with the potential for global spread. Monoclonal antibody-based treatments that have become available recently have a narrow therapeutic spectrum and are ineffective against ebolaviruses …
View article: Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection
Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection Open
View article: SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study Open